Literature DB >> 2455235

Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE).

T Inuzuka1, S Sato, H Baba, T Miyatake.   

Abstract

Camostat mesilate (FOY305), a synthetic serine protease inhibitor and has been developed as a drug for pancreatitis, is effective in suppressing acute experimental allergic encephalomyelitis in Lewis rats. Loss of weight, clinical score and yield of myelin protein from brain stem were improved by daily injection of FOY305 compared with saline from day 6 after inoculation with homogenate of guinea pig spinal cord. A significant decrease of yield of myelin has been shown here for the first time in acute EAE in Lewis rat. This is in accord with myelin breakdown demonstrated morphologically. Our study also demonstrates a significant improvement of yield of myelin protein by FOY305. Our results suggest the possibility of a clinical application of this protease inhibitor for human demyelinating diseases such as multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455235     DOI: 10.1007/bf00971537

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  15 in total

1.  A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit.

Authors:  B H WAKSMAN; R D ADAMS
Journal:  Am J Pathol       Date:  1962-08       Impact factor: 4.307

2.  Biochemical changes in central nervous system membranes in experimental allergic encephalomyelitis.

Authors:  S Salvati; D D'Urso; L Conti Devirgiliis; G Serlupi Crescenzi
Journal:  J Neurochem       Date:  1986-07       Impact factor: 5.372

3.  Myelination in rat brain: method of myelin isolation.

Authors:  W T Norton; S E Poduslo
Journal:  J Neurochem       Date:  1973-10       Impact factor: 5.372

4.  Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis.

Authors:  C F Brosnan; W Cammer; W T Norton; B R Bloom
Journal:  Nature       Date:  1980-05-22       Impact factor: 49.962

5.  Maturation of the head of bacteriophage T4. I. DNA packaging events.

Authors:  U K Laemmli; M Favre
Journal:  J Mol Biol       Date:  1973-11-15       Impact factor: 5.469

6.  Electron microscopic studies on ordinary and hyperacute experimental allergic encephalomyelitis.

Authors:  P Lampert
Journal:  Acta Neuropathol       Date:  1967-10-20       Impact factor: 17.088

7.  Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases.

Authors:  T Inuzuka; S Sato; H Baba; T Miyatake
Journal:  Acta Neurol Scand       Date:  1987-07       Impact factor: 3.209

8.  Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r-, and C1 esterase.

Authors:  Y Tamura; M Hirado; K Okamura; Y Minato; S Fujii
Journal:  Biochim Biophys Acta       Date:  1977-10-13

9.  Suppression of experimental allergic encephalomyelitis (EAE) with liposome-encapsulated protease inhibitor: therapy through the blood-brain barrier.

Authors:  T Osanai; Y Nagai
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

10.  Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis.

Authors:  M E Smith; L A Amaducci
Journal:  Neurochem Res       Date:  1982-05       Impact factor: 3.996

View more
  4 in total

1.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions.

Authors:  B Dubois; S Masure; U Hurtenbach; L Paemen; H Heremans; J van den Oord; R Sciot; T Meinhardt; G Hämmerling; G Opdenakker; B Arnold
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

2.  Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790.

Authors:  A K Hewson; T Smith; J P Leonard; M L Cuzner
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

3.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.

Authors:  K Gijbels; R E Galardy; L Steinman
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

Review 4.  Neutrophil Elastase Inhibitors and Chronic Kidney Disease.

Authors:  Elsa Bronze-da-Rocha; Alice Santos-Silva
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.